Get the Stockscreener App
753.60
1.13%
-8.745
Regeneron Pharmaceuticals Inc stock is traded at $753.60, with a volume of 166.69K.
It is down -1.13% in the last 24 hours and down -10.66% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$762.34
Open:
$758.53
24h Volume:
166.69K
Relative Volume:
0.24
Market Cap:
$82.77B
Revenue:
$13.85B
Net Income/Loss:
$4.65B
P/E Ratio:
21.49
EPS:
35.06
Net Cash Flow:
$3.32B
1W Performance:
+0.09%
1M Performance:
-10.66%
6M Performance:
-23.83%
1Y Performance:
-7.51%
1-Day Range:
$753.57
$770.00
1-Week Range:
$740.00
$770.00
52-Week Range:
$735.95
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
753.83 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.73 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
ARGX
Argen X Se Adr
|
618.67 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.19 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.52 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
COVID-19 Therapy Market Growth and Insights from 2024 to 2033 | - openPR
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors - PR Newswire
Intermediate AMD Market Growth: Key Drivers, Challenges, - openPR
(REGN) Long Term Investment Analysis - Stock Traders Daily
Erste Asset Management GmbH Makes New $42.48 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bellevue Group AG Has $28.15 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Sells 2,591 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (MIL:1REGN) 3-Year Revenue Growth Rate : 16.00% (As of Sep. 2024) - GuruFocus.com
Glenmede Trust Co. NA Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Rheumatoid Arthritis Market Expected to Experience Major Growth by 2034, According to DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH - Barchart
Single Ventricle Heart Disease Market Revenue to Expand - openPR
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Reduced by Rockefeller Capital Management L.P. - MarketBeat
Martingale Asset Management L P Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Vinva Investment Management Ltd Sells 1,055 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Regeneron Pharmaceuticals (WBO:REGN) Days Inventory : 555.65 (As of Sep. 2024) - GuruFocus.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Has $146.91 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
FORA Capital LLC Sells 4,229 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Townsquare Capital LLC Purchases 1,430 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (WBO:REGN) Interest Coverage : 89.54 (As of Sep. 2024) - GuruFocus.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors - Business Wire
Regeneron Pharmaceuticals Insiders Sold US$38m Of Shares Suggesting Hesitancy - Yahoo Finance
Cell And Gene Therapy Market Growth in Future Scope 2024-2031 | - openPR
REGN (Regeneron Pharmaceuticals) Cash Flow from Operations : $4,247 Mil (TTM As of Sep. 2024) - GuruFocus.com
Regeneron Pharmaceuticals (STU:RGO) Change In Receivables : €-474 Mil (TTM As of Sep. 2024) - GuruFocus.com
Do Wall Street Analysts Like Regeneron Pharmaceuticals Stock? - MSN
Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch
Regeneron Pharmaceuticals Unusual Options Activity - Benzinga
Ex-Regeneron Director Says FMLA Suit Should Stay In Court - Law360
Regeneron questions Dupixent marketing deal with Sanofi - Westfair Online
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire Inc.
Fmr LLC Has $10.89 Billion Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Dai ichi Life Insurance Company Ltd Sells 2,383 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Bank of Montreal Can - MarketBeat
The Manufacturers Life Insurance Company Decreases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Cerity Partners LLC - MarketBeat
Sarcopenia Market on Track for Major Expansion by 2034, According to DelveInsight | Biophytis, MyMD Pharma, N12: Erasmus Medical Center, Erasmus Medical Center, Novartis, Regeneron Pharmaceuticals - The Globe and Mail
The Law Offices of Frank R. Cruz Continues Investigation of - GlobeNewswire
Sarcopenia Market on Track for Major Expansion by 2034, - openPR
Loomis Sayles & Co. L P Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Do Options Traders Know Something About Regeneron (REGN) Stock We Don't? - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Harvest Fund Management Co. Ltd - MarketBeat
Daiwa Securities Group Inc. Acquires 2,234 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (MEX:REGN) Enterprise Value : MXN1,511,984 Mil (As of Nov. 25, 2024) - GuruFocus.com
Age-related Macular Degeneration (AMD) Drugs Market Top - openPR
Regeneron's fourth-quarter sales climb 29 percent, beating estimates - FirstWord Pharma
Swedbank AB Has $157.02 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):